NCT03334487 2018-12-26
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Withdrawn
AbbVie
Alliance for Clinical Trials in Oncology
Teva Branded Pharmaceutical Products R&D, Inc.
M.D. Anderson Cancer Center